You are here: Home » News-CM » Companies » News
Business Standard

Jubilant Life Sciences receives ANDA approcal for Darifenacin ER Tablets

Capital Market 


Jubilant Life Sciences has announced that it has received Abbreviated New Drug Application (ANDA) final approval for Darifenacin Extended-Release Tablets, 7.5 mg and 15 mg, the generic version of Enablex of Allergan Plc, which is used for the treatment of urinary incontinence.'

The Company has received 6 approvals from the USFDA during the year. As on 30 June 2016, Jubilant Life Sciences had a total of 70 ANDAs for Oral Solids filed in the US, of which 44 have been approved.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)